MCPP
1-(3-chlorophenyl)piperazine
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
mCPP (meta-chlorophenylpiperazine) is a synthetic compound of the piperazine class.[1] It is the primary active metabolite of the antidepressant trazodone, produced when the liver breaks down the drug. It amplifies serotonin activity in the brain, producing its characteristic anxiety and tension.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First synthesized in 1951 as a candidate antihistamine,[3] mCPP became the dominant research tool for probing serotonin function in psychiatry by the early 1990s.[4] Around 2004 it appeared on European drug markets in pressed tablets sold as MDMA.[5] It remains unscheduled internationally, though several countries have imposed national controls.
Subjective effects include anxiety, dysphoria, depersonalization, agitation, stimulation, and appetite suppression.[5] The experience is predominantly aversive — mounting tension and unease with almost no euphoria, making it qualitatively opposite to MDMA despite both acting through serotonin. Panic-like states, persistent agitation, and a sense of unreality are characteristic unsought effects.[6]
mCPP has low dependence potential and is not neurotoxic,[2] but one fatality is documented in a person with asthma who died after a single exposure.[7] The primary risk is unpredictability — identical doses produce blood levels up to eight times higher in some people than others due to genetic differences in how the liver processes the drug.[8] It is well-studied in clinical research, but its recreational pharmacology rests on community consensus rather than controlled dose studies.
History[edit]
Discovery
mCPP was first synthesized in 1951 by Thomas H. Wicker Jr. as part of a search for antihistamine compounds.[3] It attracted little pharmacological interest for nearly three decades. Researchers in the late 1970s recognized its potential as a tool for studying serotonin function in the brain.[1]
The serotonin probe era
By the mid-1980s, mCPP had become the dominant challenge agent in psychiatric serotonin research. Administered across studies of OCD, depression, bulimia, and panic disorder, it produced measurable hormonal responses that served as indicators of serotonin activity.[4][9] A landmark 1987 study by Zohar and Insel used mCPP to document acute worsening of OCD symptoms — early evidence for serotonergic mechanisms in the disorder.[10]
Recreational emergence and regulation
mCPP appeared on European drug markets around 2004, distributed in tablets sold as MDMA.[5][1] Recreational uptake was driven by ease of synthesis and uncontrolled legal status rather than any rewarding effects.[5] New Zealand scheduled it in 2008, Germany subsequently banned it, and the UK covered it under the Psychoactive Substances Act 2016.[3]
The name mCPP abbreviates meta-chlorophenylpiperazine, with meta denoting the chlorine atom's position on the phenyl ring. The compound carries no established street names — its recreational identity was defined by misrepresentation, typically sold under the MDMA brand in pressed tablet form indistinguishable from ecstasy.[11][12] Among forensic chemists, mCPP is notable for producing false-positive MDMA results on standard immunoassay drug screens, complicating both criminal proceedings and clinical monitoring of trazodone patients.[12][1]
Chemistry[edit]
Structural class
mCPP belongs to the phenylpiperazine family — compounds built around a piperazine ring bonded directly to a phenyl group.[1] The chlorine atom is positioned at the meta location on the ring, distinguishing it from its close analogs. Its molecular formula is C₁₀H₁₃ClN₂ (molecular weight 196.67 g/mol), built from a six-membered nitrogen-containing ring with a 3-chlorophenyl group attached.[13]
Metabolic origin
mCPP is also generated inside the body when liver enzymes break down the antidepressants trazodone, nefazodone, and etoperidone.[1] People taking these medications are continuously exposed to mCPP through normal drug processing. This makes mCPP unusual — it exists both as a standalone compound and as an active byproduct of widely prescribed antidepressants.
Pharmacology[edit]
Mechanism of action
mCPP activates serotonin receptors in the brain, and this drives most of its anxiogenic and behavioral effects.[4][14] It also prompts nerve endings to release serotonin directly — a release mechanism shared with MDMA and fenfluramine.[1][2] Unlike those compounds, repeated use does not deplete serotonin stores over time.[2][15]
Pharmacokinetics
The same dose can produce blood levels up to eight times higher in one person than another, driven by genetic differences in a liver enzyme called CYP2D6.[8] mCPP is eliminated in roughly 2.5–7 hours. Drugs that block CYP2D6 — including cocaine, paroxetine, and fluoxetine — raise mCPP blood levels and amplify all effects.[16][17]
Metabolism also produces a reactive intermediate that the body normally neutralizes.[18] This raises theoretical concerns about liver stress during prolonged exposure — most relevant for people taking trazodone, who produce mCPP continuously.
Neuroscience[edit]
Where it acts
mCPP's effects run almost entirely through the serotonin system, not dopamine.[5] This is why it produces no reward or euphoria — dopamine drives those feelings, and mCPP barely touches it. Brain imaging studies show mCPP reduces the brain's response to food, consistent with serotonin circuits that govern appetite.[19][20]
Why it matters
mCPP produces one of the most consistently induced anxiety states in psychiatric research, mediated by serotonin circuits in the amygdala and prefrontal cortex.[4] Despite acutely raising serotonin levels, repeated use does not cause lasting serotonin depletion — mCPP is non-neurotoxic.[2][15] No neuroplasticity effects have been documented.
The exact brain circuit through which mCPP produces subjective anxiety has not been mapped by neuroimaging. The significance of CYP2D6 poor metabolizer status for brain exposure and toxicity risk is unstudied.[8] Whether chronic mCPP exposure from trazodone metabolism causes receptor adaptation — and whether this shapes trazodone's therapeutic or adverse effects — remains unknown.[21] The neural basis of mCPP-induced depersonalization, documented across multiple psychiatric populations,[6] is also unknown.
Subjective Effects[edit]
The mCPP experience is predominantly aversive at every documented dose level. Anxiety and mounting tension define its character — not as adverse effects, but as the primary experience. There is almost no euphoria. The feeling is one of oppressive agitation with dysphoria and a pervasive sense of unreality.
The closest familiar reference point is MDMA — not because they are similar, but because mCPP is often sold as MDMA, and the contrast is immediate. Both act through serotonin, but where MDMA produces warmth and euphoria, mCPP produces tension and unease. A stimulant-like energy is present, but the defining quality is the negative emotional tone.
Effect Grid
Pronounced anxiety and dysphoria become the dominant experience. Unlike typical stimulants, increased dose produces greater distress rather than greater euphoria. Depersonalization is possible. Headache is common. Cognitive effects include mild confusion and difficulty concentrating.
Appetite suppression is moderate and clearly noticeable. Temperature dysregulation may manifest as alternating warmth and chills. Mild tachycardia and blood pressure elevation. Stimulation is present but overshadowed by anxiogenic character.
Functional impairment from anxiety and dysphoria makes productive activity difficult. Duration of commitment is 4-8 hours including offset.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Nausea · Restlessness · Sexual arousal suppression · Increased urination · Vasoconstriction · Dizziness · Heart rate perception changes · Wakefulness · Muscle tension · Pupil dilation · Excessive sweating · Insomnia · Bodily heaviness · Dehydration sensation · Trembling · Bruxism
Increased urination · Dizziness · Heart rate perception changes · Wakefulness · Muscle tension · Pupil dilation · Excessive sweating · Insomnia · Bodily heaviness · Dehydration sensation · Trembling · Bruxism
Confusion
Emotional lability
Timeline
Initial awareness of mild stimulation and emerging restlessness. A subtle anxiogenic undercurrent begins without clear pharmacological signature. Highly variable onset timing due to CYP2D6 polymorphisms.
Anxiety intensifies and becomes clearly drug-induced. Sympathomimetic effects become apparent — heart rate elevation, possible temperature changes. Appetite suppression develops.
Maximum anxiety, dysphoria, and depersonalization. Neuroendocrine effects peak (cortisol, prolactin elevation). Temperature dysregulation most pronounced.
Gradual attenuation of anxiety and dysphoria. Residual fatigue, headache, and cognitive dulling persist. Appetite may begin returning.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- 21 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- MDMA · other 5-HT2C agonists
Toxicity
Acute toxicity
No lethal dose has been established for mCPP. The moderate toxicity rating is inferred from pharmacological class, not from measured data.safety citation needed One non-fatal overdose is documented[22] — a woman who took three tablets reached blood levels six times the upper range for trazodone therapy and recovered with supportive care.
One fatality is documented: a 20-year-old with asthma who died of cardiorespiratory arrest after approximately 20 mg, his first exposure.[7] The probable cause was serotonin-driven airway constriction. Asthma transforms mCPP from an unpleasant compound into a potentially lethal one.
Neurotoxicity
mCPP is non-neurotoxic. Despite causing large acute serotonin elevations, repeated use does not produce lasting serotonin depletion — in direct contrast to fenfluramine and MDMA.[2][15]
Serotonin syndrome
Combining mCPP with other serotonin-raising drugs creates significant risk of serotonin syndrome — a dangerous overload state that can cause overheating, muscle rigidity, and seizures.[5] No published case of serotonin syndrome from mCPP alone has been identified, but the pharmacological basis is well established.
Chronic mCPP generation from trazodone metabolism means trazodone patients carry an ongoing serotonergic background load that may go clinically unrecognized.[21]
Liver concerns
Metabolism of mCPP produces a reactive intermediate that the body normally neutralizes.[18] No clinical liver damage has been linked to mCPP, but the theoretical concern is greatest for trazodone patients, who produce mCPP continuously.
Trazodone-generated exposure
People receiving trazodone, nefazodone, or etoperidone are continuously exposed to mCPP as an active metabolite.[1] Clinically significant mCPP levels may persist around the clock in treated patients.[21] A practical complication: mCPP produces false-positive MDMA results on standard urine drug screens.[12]
Psychological risks
Anxiety is the most consistently documented effect of mCPP and represents a real clinical risk.[4] At research doses, mCPP reliably induces panic-like states, acute dysphoria, and depersonalization in both healthy volunteers and psychiatric patients.[6] OCD patients experience acute worsening of symptoms.[10]
People with pre-existing anxiety disorders, OCD, borderline personality disorder, or psychotic spectrum conditions face heightened risk of severe distress.[5] Depersonalization occurs significantly more often than with placebo and appears to be distinct from baseline anxiety or depression.[6]
Tolerance and dependence
mCPP has low abuse and dependence potential. It produces no reinforcement in standard animal or human paradigms.[5] No withdrawal has been documented.
Indirect evidence suggests serotonin receptors may desensitize with repeated exposure,citation needed but no controlled tolerance study in humans has been published.
Drug interactions
Serotonergic combinations
Any drug that raises serotonin — SSRIs, SNRIs, MAOIs, triptans, or tramadol — increases serotonin syndrome risk when combined with mCPP.[5] Prior MDMA use alters mCPP's hormonal effects, initially blunting them and later amplifying them.[23][24] Acute co-administration carries additive risk.
CYP2D6 inhibitors
Cocaine blocks the enzyme that breaks down mCPP, causing blood levels to rise.[16] mCPP has been documented as an adulterant in cocaine, making this a real-world scenario. Paroxetine, fluoxetine, and diltiazem produce equivalent elevation.[17]
Trazodone and related antidepressants
People taking trazodone, nefazodone, or etoperidone are already producing mCPP through normal metabolism.[1] Additional mCPP exposure produces additive effects. Clinically significant levels persist around the clock in treated patients.[21]
Alcohol
Alcohol was present in the only documented non-fatal mCPP overdose.[22] No controlled study of this combination has been published. Additive depressant effects are pharmacologically plausible but uncharacterized.
Interaction severity notes
Tramadol and cocaine interactions are listed as potentially lethal. No published case reports of fatal outcomes from these specific combinations have been identified. The serotonin syndrome mechanism for tramadol and the CYP2D6 inhibition mechanism for cocaine are pharmacologically well-supported, but the lethal severity classification for both lacks direct case documentation.safety citation needed
Contraindications
Asthma and reactive airways disease
The single documented mCPP fatality occurred in a person with pre-existing asthma.[7] Asthma and reactive airways disease constitute an absolute contraindication for intentional mCPP exposure. People with asthma receiving trazodone may also warrant clinical monitoring.
Psychiatric conditions
Pre-existing anxiety disorders, OCD, borderline personality disorder, and psychotic spectrum conditions increase the risk of severe distress.[5] mCPP reliably worsens OCD symptoms[10] and induces depersonalization in vulnerable populations.[6]
Concurrent serotonergic medication
SSRIs, SNRIs, MAOIs, triptans, and tramadol constitute a relative-to-absolute contraindication depending on the agent and dose, due to serotonin syndrome risk.[5] MAOI co-administration carries the highest risk.
CYP2D6 poor metabolizer status
People with CYP2D6 poor metabolizer genetics or those taking CYP2D6 inhibitors will reach substantially higher blood levels from the same dose, amplifying all dose-dependent risks.[16][17]
Cardiovascular conditions
mCPP produces mild elevations in blood pressure and heart rate.[9][25] Pre-existing heart conditions represent a relative contraindication.
Harm Reduction[edit]
Forms & Identification
mCPP is most commonly encountered in pressed tablet form, often stamped with logos identical to those on MDMA tablets.[11][12] Visual inspection cannot distinguish mCPP from MDMA. Reagent testing is essential — mCPP and MDMA produce distinct color reactions with standard kits.
mCPP cross-reacts with standard Ecstasy immunoassay urine tests, producing false-positive MDMA results.[12] This affects both recreational users and people taking trazodone. Only confirmatory laboratory testing (GC-MS or LC-MS) can reliably distinguish them in biological samples.
Guidelines
- Test all tablets with reagent kits before ingestion — mCPP pressed as ecstasy is common
- Start with the lowest available amount and wait at least 2 hours before considering re-dosing, given the extreme pharmacokinetic variability between individuals[8]
- Have a sober, trusted companion present
- Ensure a calm, familiar environment with easy access to quiet space
- Stay hydrated but avoid excessive water intake
- If effects are primarily anxious and dysphoric rather than empathogenic, consider that the substance may not be what was expected
Set & Setting
mCPP is fundamentally anxiogenic — set and setting significantly affect distress severity. Unfamiliar, crowded, or high-stimulation environments amplify the anxiety and dysphoria that define the experience. People who unknowingly take mCPP believing it to be MDMA face compounded distress from both the pharmacological effects and the realization that the expected experience will not arrive.
Aftercare & integration. The mCPP experience is predominantly negative, and aftercare focuses on recovery from acute psychological distress rather than integration of meaningful content. Anxiety and dysphoria typically resolve within hours of elimination, but residual tension, low mood, and fatigue may persist for a day.
Rest and adequate sleep are the primary recovery tools. Familiar environments, trusted company, and light nutrition support the return to baseline. If depersonalization symptoms persist beyond 24 hours, consider consulting a healthcare provider.
Recovery & Support
mCPP has low dependence potential, and compulsive use is rare given the aversive effect profile. Most exposure is inadvertent — from tablets sold as MDMA — rather than sought. For people experiencing repeated involuntary exposure through adulterated drug supply, harm reduction services and drug checking programs offer the most effective pathway to avoiding future mCPP encounters.
People taking trazodone who experience adverse effects attributable to mCPP metabolite accumulation should discuss alternatives with their prescribing physician.[21] Support resources for substance-related concerns include SAMHSA's National Helpline (1-800-662-4357) and equivalent services in other jurisdictions.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Difficulty breathing or wheezing (especially in people with asthma), chest pain, severe uncontrollable panic, loss of consciousness, high body temperature, rigid muscles, or rapid involuntary eye movements. The critical distinction between uncomfortable and dangerous centers on breathing difficulty, chest symptoms, or complete loss of contact with reality.
Immediate steps:
- 1. Call emergency services if breathing difficulty, chest pain, seizure, or loss of consciousness occurs
- 2. Keep the person in a quiet, calm environment
- 3. If unconscious but breathing, place in the recovery position
- 4. Monitor breathing continuously — the documented fatality involved progressive respiratory failure
- 5. Do not restrain unless there is immediate danger of self-harm
- 6. Do not induce vomiting
What to tell the dispatcher: Name the substance (mCPP or piperazine), estimated amount taken, time of ingestion, and current symptoms. Note any pre-existing conditions, especially asthma. Good Samaritan laws in many jurisdictions protect people who call for help during drug emergencies.
Legal Status[edit]
mCPP remains unscheduled under international drug control conventions.[5]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | Not controlled under the Controlled Substances Act. The Federal Analogue Act may apply if sold for human consumption.citation needed |
| New Zealand | Class C (Misuse of Drugs Act 1975) | Scheduled effective April 2008; possession illegal from October 2008.[3] |
| Germany | Controlled substance | Banned; specific scheduling date not confirmed in primary sources.[3] |
| United Kingdom | Prohibited | Covered under the Psychoactive Substances Act 2016 blanket prohibition.[3] |
| Australia | Not confirmed | No primary source identified; verification via TGA/Poisons Standard recommended.citation needed |
| Canada | Not confirmed | No primary source identified.citation needed |
| European Union | Variable by member state | No EU-wide scheduling; some member states have national controls.[5] |
Forensic considerations
mCPP cross-reacts with the Ecstasy EMIT II immunoassay, producing false-positive MDMA results in standard urine drug testing.[12] This affects both recreational users and trazodone patients.[1] The implications extend to workplace drug testing, criminal justice proceedings, and clinical monitoring programs where a positive MDMA screen may trigger consequences based on a misidentified substance.
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Always verify current laws in the relevant jurisdiction before acting on this information.
references
- [1]
- [2] ^abcdefBaumann MH, Bulling S, Benaderet TS, Saha K, Ayestas MA, Partilla JS, Ali SF, Stockner T, Rothman RB, Sandtner W, Sitte HH (2014) Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates — Neuropsychopharmacology doi:10.1038/npp.2013.331
- [3]
- [4]
- [5]
- [6]